JPRN-UMIN000012224已完成未知
The examination of effects of switching to GLP-1 analog liraglutide or adding on insulin glargine once daily for type 2 diabetes controlled insufficiently by DPP-4 inhibitors and other oral anti-diabetic agents combination (multicenter study). - Basal-supported Oral therapy Or Switching to GLP-1 receptor agonist for Type 2 diabetes (BOOST2) study
Toho University School of Medicine, Division of diabetes, metabolism and endocrinology0 个研究点目标入组 60 人开始时间: 2013年11月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
For poorly controlled T2DM on DPP-4i-based OAD therapy, switching to single-dose liraglutide to enhance incretin signaling is as effective as dose-titrated basal IGlar, but significant BW reduction was only seen in the liraglutide group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Type 1 diabetes mellitus patients (2) Patients with severe liver disease (3) Patients with severe renal disease (4) Patients who had myocardial infarction within 3 months, or obvious heart failure case (5) Patients with severe pancreas disease (6) Patients having a cancer (7) Patients with hemoglobin (Hb) less than 11 g/dL (8) Patients that the number of the platelets is less than 100,000 /mm3 (9) Patients with high diabetic neuropathy (10) Patients having a proliferative retinopathy (11) Patients with a serious infectious disease or a serious injury (12) Patients with bowel disease or ileus factors (13) Chronic enteropathy patients with the digestion and absorption abnormality (14) Excessive common custom drinker (15) A pregnant woman or the woman who may be pregnant (16) Patients who was infected with hepatitis B virus or hepatitis C virus (17) In addition, the patient who judged inappropriate by an attendant physician
研究者
相似试验
已完成
4 期
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes MellitusType 1 DiabetesNCT01235819Command Hospital, India20
已完成
不适用
Effect of switching from a combination therapy using DPP-4 inhibitor and insulin degludec to insulin degludec/liraglutide on blood glucose fluctuation in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000039460Hokkaido University Hospital15
已完成
不适用
Impact of switching from once-weekly GLP1receptor agonist to once-weekly DPP4inhibitor(Omaligliptin)therapy on glycemic control parameters in type 2 diabetes patients undergoing hemodialysis.JPRN-UMIN000029739Minamiosaka hospital
已完成
不适用
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01299012University at Buffalo30
已完成
4 期
Effects of DPP4 Inhibitor Versus SGLT2 InhibitorIschemic Heart DiseaseDiabetes Mellitus, Type 2NCT03178591Chiang Mai University43